×

Otonomy to Host Investor and Analyst Day on October 7, 2015

SAN DIEGO, Sept. 30, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC) will host an Investor and Analyst Day on Wednesday, October 7, 2015, from 8:30 a.m. to 11:30 a.m. EDT (5:30 a.m. to 8:30 a.m. PDT) in New York City. David A. Weber, Ph.D., president and chief executive officer, and other members of the Otonomy management team will provide a comprehensive update of commercialization plans for AuriPro™ in patients undergoing ear tube surgery, a review of the Phase 3 clinical trial program for OTO-104 in Ménière's disease, and an introduction to the OTO-311 program for tinnitus. In addition, notable otolaryngology experts will discuss their perspective on these otic disorders and Otonomy's pipeline of drug candidates.

Interested parties may access a live audio webcast and slides of the presentations on the investor section of Otonomy's website at www.otonomy.com beginning at 8:30 a.m. EDT. An archive of the webcast will be available shortly after the event and can be viewed at the same link for a limited time.

About Otonomy

Otonomy is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. Otonomy's proprietary technology provides sustained exposure of drugs to the ear following a single administration. Otonomy has three product candidates in development. AuriPro™ is an antibiotic that has completed Phase 3 clinical trials in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery, and the FDA has assigned a PDUFA action date of December 25, 2015 for the company's New Drug Application. OTO-104 is a steroid that has completed a Phase 2b clinical trial in 154 patients with Ménière's disease. Based on these results, Otonomy intends to initiate two parallel Phase 3 trials for OTO-104 in Ménière's disease patients with at least one trial initiated by the end of 2015. OTO-311 is an NMDA receptor antagonist in development as a treatment for tinnitus. For additional information please visit www.otonomy.com.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Otonomy's future financial or operating performance. Forward-looking statements in this press release include, but are not limited to, the initiation, timing and design of Otonomy's Phase 3 clinical trials with OTO-104 and the timing of the launch of AuriPro™. Otonomy's expectations regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties. Actual results may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to: the uncertainties inherent in the clinical drug development process, including, without limitation, Otonomy's ability to adequately demonstrate the safety and efficacy of its product candidates, the preclinical and clinical results for its product candidates, which may not support further development of product candidates, and challenges related to patient enrollment in clinical trials; Otonomy's ability to obtain regulatory approval for its product candidates; side effects or adverse events associated with Otonomy's product candidates; developments related to competitors and the industry; Otonomy's dependence on third parties to conduct preclinical studies and clinical trials; Otonomy's dependence on third parties for the manufacture of products; Otonomy's dependence on a small number of suppliers for raw materials; Otonomy's ability to protect its intellectual property related to product candidates in the United States and throughout the world; and other risks. Otonomy undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

CONTACT: MEDIA CONTACT: Canale Communications Heidi Chokeir, Ph.D. Senior Vice President (619) 849-5377 heidi@canalecomm.com INVESTOR CONTACT: Westwicke Partners, LLC Robert H. Uhl Managing Director (858) 356-5932 robert.uhl@westwicke.com

Source:Otonomy, Inc.